Neurogene Inc. - 8-K Filing
Neurogene Inc. filed to report first-quarter 2026 financial results, including $25.2 million in R&D expenses and a net loss of $30.9 million for the three months ended March 31, 2026. The company also announced that ~90% of participants have been dosed in its Embolden™ registrational trial for NGN-401 gene therapy targeting Rett syndrome, with completion expected by Q2 2026. (Items: 2.02 and Exhibits 99)
Tickers: $NGNE